Interleukin 2 - Repertoire Immune Medicines
Latest Information Update: 10 Mar 2022
At a glance
- Originator Repertoire Immune Medicines
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Mar 2022 Discontinued for Cancer in USA (Parenteral) (Repertoire Immune Medicines pipeline, March 2022)
- 10 Feb 2021 Early research in Cancer in USA (Parenteral) before February 2021 (Repertoire Immune Medicines' pipeline, February 2021)